# [Comment] Sacituzumab tirumotecan in previously treated endometrial cancer

Source: [thelancet.com](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)02250-6/fulltext?rss=yes) · 2026-11-21 · Medicine
Page: https://themorning.science/story/comment-sacituzumab-tirumotecan-in-previously-treated-endometrial-cancer-5756853b455c7bb3
Kind: research · Impact: medium

## In brief

- Endometrial cancer is the most common gynaecological cancer in high-income countries and the sixth most common cancer in women worldwide.
- Both incidence and mortality of endometrial cancer are increasing, making it one of few cancers with this trend.
- A Lancet comment discusses sacituzumab tirumotecan in previously treated endometrial cancer.

## Why it matters

Rising incidence and mortality make effective treatment options for patients whose cancer has already been treated an important concern for oncology researchers and clinicians.

## Timeline

- 2026-11-21: Lancet comment on sacituzumab tirumotecan in previously treated endometrial cancer published

## Coverage

- [[Comment] Sacituzumab tirumotecan in previously treated endometrial cancer](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)02250-6/fulltext?rss=yes) — thelancet.com, 2026-11-21

Tags: endometrial cancer, gynaecological cancer, oncology, sacituzumab tirumotecan, clinical comment

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science
